CL2018001157A1 - Formulación de combinación de dosis fija, eflornitina y sulindaco. - Google Patents

Formulación de combinación de dosis fija, eflornitina y sulindaco.

Info

Publication number
CL2018001157A1
CL2018001157A1 CL2018001157A CL2018001157A CL2018001157A1 CL 2018001157 A1 CL2018001157 A1 CL 2018001157A1 CL 2018001157 A CL2018001157 A CL 2018001157A CL 2018001157 A CL2018001157 A CL 2018001157A CL 2018001157 A1 CL2018001157 A1 CL 2018001157A1
Authority
CL
Chile
Prior art keywords
fixed dose
eflornithine
sulindac
formulation
dose combination
Prior art date
Application number
CL2018001157A
Other languages
English (en)
Inventor
Patrick Shannon
Gonzalez Roberto Carlos Bravo
Jean Ducassou
Original Assignee
Cancer Prevention Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Prevention Pharmaceuticals Inc filed Critical Cancer Prevention Pharmaceuticals Inc
Publication of CL2018001157A1 publication Critical patent/CL2018001157A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

COMPOSICION QUE COMPRENDE UNA COMBINACION  DE DOSIS FIJA DE EFLORNITINA Y UN ANTIINFLAMATORIO NO ESTEROIDEO (NSAID) O UN METABOLITO DEL MISMO, UTIL PARA EL TRATAMIENTO DEL CANCER.
CL2018001157A 2015-10-30 2018-04-30 Formulación de combinación de dosis fija, eflornitina y sulindaco. CL2018001157A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562248810P 2015-10-30 2015-10-30
US201662358698P 2016-07-06 2016-07-06
EP16306429 2016-10-28
EP16306430 2016-10-28

Publications (1)

Publication Number Publication Date
CL2018001157A1 true CL2018001157A1 (es) 2018-09-07

Family

ID=57256487

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001157A CL2018001157A1 (es) 2015-10-30 2018-04-30 Formulación de combinación de dosis fija, eflornitina y sulindaco.

Country Status (14)

Country Link
US (3) US10973790B2 (es)
EP (1) EP3368029A1 (es)
JP (2) JP2018536707A (es)
KR (1) KR20180069068A (es)
CN (1) CN108366982A (es)
AU (1) AU2016343851B2 (es)
BR (1) BR112018008651A2 (es)
CA (1) CA3003149C (es)
CL (1) CL2018001157A1 (es)
CO (1) CO2018005491A2 (es)
HK (1) HK1258284A1 (es)
IL (1) IL259009A (es)
MA (1) MA43114A (es)
MX (1) MX2018005350A (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368029A1 (en) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
NZ752894A (en) * 2016-10-06 2023-05-26 Orbus Therapeutics Inc Formulations for administration of eflornithine
TW202110431A (zh) * 2019-05-17 2021-03-16 美商癌症預防製藥股份有限公司 治療家族性腺瘤性瘜肉症之方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4413141A (en) 1977-07-11 1983-11-01 Merrell Toraude Et Compagnie 2-(Difluoromethyl)-2,5-diaminopentanoic acid
US4330559A (en) 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
US4309442A (en) 1977-07-11 1982-01-05 Merrell Toraude Et Compagnie Method for controlling fertility in mammals
US4499072A (en) 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4859452A (en) 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
US4925835A (en) 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
FR2706255B1 (fr) 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
AU5200098A (en) * 1996-11-01 1998-05-29 Ilex Oncology, Inc. Sustained release formulation containing dfmo
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
AU754864B2 (en) 1998-03-28 2002-11-28 Arizona Board Of Regents On Behalf Of The University Of Arizona, The DFMO and sulindac combination in cancer chemoprevention
US7700568B2 (en) 1998-06-30 2010-04-20 Sloan-Kettering Institute For Cancer Research Uses of DNA-PK
IL143901A0 (en) 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
US20050037090A1 (en) 1998-12-23 2005-02-17 Mckearn John P. Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
US6753422B2 (en) 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
US6573290B1 (en) 1999-05-17 2003-06-03 Ilex Oncology, Inc. DFMO and celecoxib in combination for cancer chemoprevention and therapy
WO2001068076A2 (en) 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
US6602910B2 (en) 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
JP2004506683A (ja) 2000-08-24 2004-03-04 ザ　リージェンツ　オブ　ザ　ユニバーシティ　オブ　カリフォルニア α−ジフルオロメチルオルニチン（ＤＦＭＯ）は、ヒト前立腺におけるポリアミンレベルを抑制する
GB0125492D0 (en) * 2001-10-24 2001-12-12 Astrazeneca Ab Formulation
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
EP1575584A4 (en) * 2002-11-29 2006-02-01 Forest Laboratories METHOD FOR THE TREATMENT OF ACUTE CHARACTERIZATION BY UNIFORM FORMING WITH IBUPROFEN AND OXYCODON
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
JP2009501801A (ja) * 2005-07-18 2009-01-22 ホライゾン セラピューティクス， インコーポレイテッド イブプロフェンとファモチジンとを含有する医薬およびその投与
WO2007075673A1 (en) 2005-12-20 2007-07-05 University Of Hawaii Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
WO2008011426A2 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
US8829021B2 (en) 2007-08-01 2014-09-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of pediatric tumors
WO2009022670A1 (ja) * 2007-08-10 2009-02-19 Takeda Pharmaceutical Company Limited 速崩壊性錠剤
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
AU2009221765B2 (en) 2008-03-05 2015-05-07 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
CA2746320C (en) 2008-12-08 2014-07-15 The Procter & Gamble Company Personal care composition in the form of an article having a hydrophobic surface-resident coating
CA2761946A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of California, A California Corporation Carcinoma diagnosis and treatment, based on odc1 genotype
SG2014011969A (en) 2009-05-20 2014-09-26 Ranbaxy Lab Ltd Liquid dosage forms of isotretinoin
CN101898978A (zh) 2009-05-31 2010-12-01 徐锋 依氟鸟氨酸前药和偶合物及其使用方法
US20110256161A1 (en) 2010-04-19 2011-10-20 Aminex Therapeutics Inc. Methods for enhancing immune response
EP2563936B1 (en) 2010-04-29 2018-03-14 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
US20130217743A1 (en) 2010-05-14 2013-08-22 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
US8853423B2 (en) * 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
KR101834026B1 (ko) 2010-06-19 2018-03-02 메모리얼 슬로안-케터링 캔서 센터 항-ｇｄ2 항체
PT2912193T (pt) 2012-10-29 2018-11-29 Arizona Board Of Regents On Behalf Of Univ Of Arizona Marcadores preditivos para terapêuticas de cancro de inibidor de poliamina
GB2513299A (en) 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells
PT3421033T (pt) * 2013-10-07 2022-09-23 Bristol Myers Squibb Holdings Ireland Formulação de atazanavir e cobicistat para tratamento de vih
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
JP2017519770A (ja) 2014-06-18 2017-07-20 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティ オブ アリゾナ Ｏｄｃ１遺伝子型に基づく癌腫の診断および処置
US20190046484A1 (en) 2015-02-12 2019-02-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
WO2017075576A1 (en) 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
EP3368029A1 (en) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation

Also Published As

Publication number Publication date
KR20180069068A (ko) 2018-06-22
JP2018536707A (ja) 2018-12-13
US20210267926A1 (en) 2021-09-02
MA43114A (fr) 2018-09-05
US20230172887A1 (en) 2023-06-08
AU2016343851B2 (en) 2022-04-07
US10973790B2 (en) 2021-04-13
IL259009A (en) 2018-07-31
JP2022028814A (ja) 2022-02-16
AU2016343851A1 (en) 2018-05-10
CA3003149A1 (en) 2017-05-04
HK1258284A1 (zh) 2019-11-08
CN108366982A (zh) 2018-08-03
US11925613B2 (en) 2024-03-12
CA3003149C (en) 2023-10-31
MX2018005350A (es) 2018-08-14
CO2018005491A2 (es) 2018-06-12
EP3368029A1 (en) 2018-09-05
US20200009098A1 (en) 2020-01-09
BR112018008651A2 (pt) 2018-10-30
US11529326B2 (en) 2022-12-20

Similar Documents

Publication Publication Date Title
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2016002495A1 (es) Derivados de piridina macrocíclicos .
CL2020003174S1 (es) Dispositivo para administración de dosis.
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2018001157A1 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
CL2017000662A1 (es) Inhibidores de la histona desmetilasa.
DK3394045T3 (da) Co-krystal, fremstillingsfremgangsmåde deraf og medikament som indeholder co-krystal.
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων
BR112017004745A2 (pt) adição a um aplicador médico
DK3141088T3 (da) Feedback-billeddannelse med ultralav dosis ved hjælp af laser-compton-røntgen- og laser-compton-gamma-strålekilder